Telitacicept (BlyS/APRIL inhibitor) ph3 in RA wholly in China, after SLE approval there (SLE trial now w global sites) Efficacy okay, no better than other b/tsDMARDs What's the hook here, in a crowded RA market incl biosimilars? Safety does look good though #ACR23 L20 @RheumNow https://t.co/UzQ0f18E2A